Zevra Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases. The company's lead product, MIPLYFFA (arimoclomol), is an oral treatment approved by the U.S. Food and Drug Administration for the neurological manifestations of Niemann-Pick disease type C (NPC) in adult and pediatric patients. MIPLYFFA is also under review by the European Medicines Agency for marketing authorization in the European Union. Zevra’s portfolio includes OLPRUVA (sodium phenylbutyrate), a commercially available oral suspension for the treatment of urea cycle disorders (UCDs) in the United States, and celiprolol, a clinical-stage candidate currently in a Phase 3 trial for Vascular Ehlers-Danlos syndrome (VEDS). The company also holds rights to AZSTARYS (serdexmethylphenidate and dexmethylphenidate) for attention deficit and hyperactivity disorder (ADHD), for which it receives royalties and milestones. Zevra serves patients in the United States and Europe, utilizing a global expanded access program to provide MIPLYFFA to patients in select territories outside of Europe. The company acquired Acer Therapeutics in 2023 to add OLPRUVA and celiprolol to its portfolio and previously developed AZSTARYS using its proprietary Ligand Activated Technology platform.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage zevra.com
Sector Healthcare IR page investors.zevra.com
Tags
rare diseases, neurodegenerative diseases, niemann-pick disease type c, urea cycle disorders, vascular ehlers-danlos syndrome, oral therapeutics, clinical development, commercialization, MIPLYFFA, arimoclomol, OLPRUVA, sodium phenylbutyrate, celiprolol, AZSTARYS, serdexmethylphenidate, dexmethylphenidate, Acer Therapeutics Inc., Orphazyme A/S, Ligand Activated Technology, KP1077IH, KP1077N
Press page —

Metrics

Valuation  
Market cap $ 668.545M
Market cap (USD) $ 668.545M
P/E 9.30
PEG —
P/BV 2.80
P/S 4.52
P/OCF 17.26
P/FCF 17.47
Dividend yield —
Turnover / mcap —
Returns  
ROE 85.7%
ROI 38.4%
ROIC -27.9%
Profit margin 78.2%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 40.0%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 30
Quality score 11.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Revenue 106.47M 23.612M 27.461M 10.458M 28.65M 13.288M 12.839M — — — 0 0
Net profit 83.229M -105.511M -46.049M -41.543M -8.555M -12.76M -24.522M -56.466M -43.386M -16.516M -54.664M -24.455M
Free cash flow -2.433M -69.665M -33.831M -18.81M 10.337M -1.972M -23.763M -54.224M -33.281M -30.415M -20.403M -14.72M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Share price 8.96 8.34 6.55 4.59 8.71 11.2 0.38 1.78 4.05 2.95 19.86 —
Price performance 12m 0.07 0.27 0.43 -0.47 -0.22 28.18 -0.78 -0.56 0.37 -0.85 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 5M 2.01M 0.00 1.68M 2.44M 1.42M 7.19M 16.1M 10.2M —
↳ YoY growth -59.9% -100.0% +45.3% -41.8% +405.6% +124.3% -36.9%
↳ 5y CAGR -22.3% +29.1% +43.4%
Borrowings, non-current (USD) — — — — — — — 5.07M 59.5M 61.9M
Lease liabilities (USD) — — — 2.19M 1.91M 1.59M 1.32M 999,000 792,000 1.28M
Cash and deposits (USD) 16.8M 10.9M 18.4M 3.22M 4.21M 112M 65.5M 43M 33.8M 62.4M
Intangible assets (USD) — — — — — — 0.00 69.2M 69M 6.42M
Right-of-use assets (USD) — — — 1.54M 1.35M 1.14M 988,000 790,000 657,000 1.21M
Net debt (borrowings + leases - cash) (USD) — — — — — — — -37M 26.5M 800,000
Cash flow detail
Operating cash flow (USD) -29.8M -33.1M -54.2M -23.7M -1.94M 10.4M -18.7M -33.5M -69.7M -1.6M
Purchases of property, plant and equipment (USD) -643,000 -181,000 -21,000 -26,000 -33,000 -102,000 -93,000 -296,000 0.00 -835,000
Purchases of intangible assets (USD) — — — — — — — 0.00 -6M 0.00
Change in inventories (cash effect) (USD) — — — — — 0.00 147,000 206,000 -8.87M -1.31M
Change in payables (cash effect) (USD) 1.12M -801,000 -1.64M -3.79M 931,000 -1.11M 3.13M 11.1M -3.6M -15.6M
Share buybacks (cash effect) (USD) — — — — 0.00 -2.81M -4.72M -3.45M 0.00 —
Interest paid (cash effect) (USD) -3.29M -5.72M -5.59M -5.36M -78,000 -218,000 -321,000 -456,000 -5.26M -5.33M
Share-based compensation (USD) 6.6M 4.56M 6.5M 4.41M 2.49M 2.44M 4.29M 5.95M 14.9M 12.6M
Free cash flow (OCF - PPE - intangibles) (USD) -30.4M -33.3M -54.2M -23.8M -1.97M 10.3M -18.8M -33.8M -75.7M -2.43M
Income detail
Research and development expense (USD) 20.5M 20.6M 41.8M 19.4M 8.84M 10.2M 19.6M 39.8M 42.1M 12.7M
↳ 5y CAGR +65.5% +10.3% -8.7% -13.1% -1.0% -1.0% +16.7% +7.6%
Total comprehensive income (USD) — — — — — -62.9M -41.4M -46.2M -105M 81.8M
Comprehensive income to owners (USD) — — — — — -62.9M -41.4M -46.2M -105M 81.8M
Reported Mar 10, 2017 Mar 30, 2018 Nov 14, 2019 Feb 28, 2020 Mar 31, 2022 Mar 7, 2023 Apr 1, 2024 Mar 12, 2025 Mar 12, 2025 Mar 9, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 3, 2026

PDF Version

$37.8 million net revenue for Q3 2026, driven by $34.0 million in revenue from MIPLYFFA

45% increase in total net revenue over Q3 2025

Operational execution fueled strong cash position of $270.9 million

Company to host conference call and webcast TODAY, November 3, 2026, at 4:30 p.m. ET

BOSTON, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today reported its financial results for the third quarter ended September 30, 2026.

“In the third quarter, we made continued progress across our business, building on MIPLYFFA's commercial performance in the U.S. and advancing our pipeline in support of our mission to redefine what’s possible in bringing life-changing therapies to people living with rare disease,” said Neil F. McFarlane, Zevra's President and Chief Executive Officer. “We remain focused on reaching more people living with Niemann-Pick disease type C, advancing celiprolol for vascular Ehlers-Danlos syndrome, and pursuing European access to arimoclomol. Our strong financial position enables us to advance these priorities while continuing to make arimoclomol available to eligible patients through our global Expanded Access Program.”

MIPLYFFA® (arimoclomol) Highlights

  • U.S.: Received 13 MIPLYFFA prescription enrollment forms for Niemann-Pick disease type C (NPC) during Q3 2026, bringing the total to 197 since product launch.

  • EU: The Company requested a re-examination of its Marketing Authorisation Application for arimoclomol for the treatment of NPC and is awaiting the outcome of the process.

  • Global Expanded Access Program (EAP): As of September 30, 2026, 134 patients were enrolled in the global EAP.

  • Following the publication of its pediatric data in Molecular Genetics and Metabolism Reports, Zevra met with the U.S. Food and Drug Administration (FDA) to discuss a potential supplemental New Drug Application (sNDA) for MIPLYFFA in infants less than 24 months of age. Company anticipates filing sNDA in Q1 2027.

Pipeline and Innovation Highlights

  • Enrolled six patients in the event-driven Phase 3 DiSCOVER trial of celiprolol for the treatment of Vascular Ehlers-Danlos Syndrome during Q3 2026, bringing the total number of enrolled patients to 72, with a total of four confirmed events. The Company recently engaged with the FDA for a Type C meeting to discuss a potential submission strategy for celiprolol.

Q3 2026****Financial Highlights

  • Revenue, Net: $37.8 million for Q3 2026, which includes $34.0 million of MIPLYFFA net revenue, $0.2 million of OLPRUVA net revenue, and $3.6 million in net reimbursements from our global EAP. This was an increase in total net revenue of $11.7 million compared to $26.1 million in Q3 2025.

  • Cost of Product Revenue: $1.8 million for Q3 2026, excluding non-cash intangible asset amortization. Cost of product revenue for Q3 2025 was $1.2 million, excluding non-cash intangible asset amortization.

  • Operating Expenses: $24.1 million for Q3 2026, which includes non-cash stock compensation expense of $2.7 million. Total operating expenses for Q3 2025 were $20.4 million.

    • R&D expense was $4.9 million for Q3 2026, which was an increase of $1.5 million compared to $3.4 million for Q3 2025, due primarily to our ongoing investment in arimoclomol efforts and in the celiprolol development program.
    • SG&A expense was $19.1 million for Q3 2026, which was an increase of $2.2 million compared to $16.9 million for Q3 2025, due primarily to commercial and infrastructure related costs.
  • Net income (loss)****: Net income of $19.2 million, or $0.31 per basic and $0.26 diluted share for Q3 2026, compared to a net (loss) of $(0.5) million, or $(0.01) per basic and diluted share for Q3 2025.

  • In Q3 2026, the Company recognized $5.1 million in noncash income due to fair value adjustments related to warrant and contingent value rights (CVR) liability compared to $(5.5) million of noncash expense in Q3 2025.

  • Cash Position: Cash, cash equivalents and investments were $270.9 million as of September 30, 2026. Based on its current operating forecast, the Company believes available financial resources are sufficient to execute on its strategic priorities.

  • **Common and Fully Diluted Shares O/S:**As of September 30, 2026, total shares of common stock outstanding were 59,439,959, and fully diluted common shares were 68,968,909, which included 6,999,571 shares issuable from outstanding awards under equity incentive plans, and 2,529,379 shares issuable upon exercise of warrants.

Conference Call Information

Zevra will host a conference call and audio webcast TODAY at 4:30 p.m. ET to discuss its corporate update and financial results for the third quarter 2026.

A link to the audio webcast is accessible on the “Events & Presentations” page in the Investor Relations section of the Zevra's website at investors.zevra.com. A replay of the webcast will be available for 90 days beginning at approximately 5:30 p.m. ET on November 3, 2026.

Additionally, interested participants and investors may access the conference call by dialing either:

  • (800) 274-8461 (United States)

  • +1 (203) 518-9814 (International)

  • Conference ID: ZVRAQ326

About MIPLYFFA® (arimoclomol)

MIPLYFFA (arimoclomol) is Zevra’s approved therapy for the treatment of Niemann-Pick disease type C (NPC). Approved by the U.S. Food and Drug Administration on Sep. 20, 2024, MIPLYFFA (arimoclomol) increases the activation of the transcription factors EB (TFEB) and E3 (TFE3) resulting in the upregulation of coordinated lysosomal expression and regulation (CLEAR) genes. MIPLYFFA has also been shown to reduce unesterified cholesterol in the lysosomes of human NPC fibroblasts. The clinical significance of these findings is not fully understood. In the pivotal phase 3 trial, MIPLYFFA halted disease progression compared to placebo over the one-year duration of the trial when measured by the only validated disease progression measurement tool, the NPC Clinical Severity Scale. MIPLYFFA has also received Orphan Medicinal Product designation by the European Medicines Agency (EMA) for the treatment of NPC. The extensive data generated for MIPLYFFA has shown long-term, meaningful clinical outcomes with more than 5 years of patient experience across more than 270 NPC patients worldwide through a Phase 2/3 clinical trial, Open-Label Extension (OLE) study, Expanded Access Programs (EAP), and a pediatric sub-study, which is the most expansive clinical development program in NPC to date. Zevra has submitted a Marketing Authorization Application to the European Medicines Agency for the evaluation of arimoclomol for the treatment of Niemann-Pick disease type C.

INDICATIONS AND USAGE

MIPLYFFA is indicated for use in combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adult and pediatric patients 2 years of age and older.

IMPORTANT SAFETY INFORMATION

**Hypersensitivity Reactions:**Hypersensitivity reactions such as urticaria and angioedema have been reported in patients treated with MIPLYFFA during Trial 1: two patients reported both urticaria and angioedema (6%) and one patient (3%) experienced urticaria alone within the first two months of treatment. Discontinue MIPLYFFA in patients who develop severe hypersensitivity reactions. If a mild or moderate hypersensitivity reaction occurs, stop MIPLYFFA and treat promptly. Monitor the patient until signs and symptoms resolve.

**Embryofetal Toxicity:**MIPLYFFA may cause embryofetal harm when administered during pregnancy based on findings from animal reproduction studies. Advise pregnant females of the potential risk to the fetus and consider pregnancy planning and prevention for females of reproductive potential.

**Increased Creatinine without Affecting Glomerular Function:**Across clinical trials of MIPLYFFA, mean increases in serum creatinine of 10% to 20% compared to baseline were reported. These increases occurred mostly in the first month of MIPLYFFA treatment and were not associated with changes in glomerular function.

During MIPLYFFA treatment, use alternative measures that are not based on creatinine to assess renal function. Increases in creatinine reversed upon MIPLYFFA discontinuation.

The most common adverse reactions in Trial 1 (≥15%) in MIPLYFFA-treated patients who also received miglustat were upper respiratory tract infection, diarrhea, and decreased weight.

Three (6%) of the MIPLYFFA-treated patients had the following adverse reactions that led to withdrawal from Trial 1: increased serum creatinine (one patient), and progressive urticaria and angioedema (two patients). Serious adverse reactions reported in MIPLYFFA-treated patients were hypersensitivity reactions including urticaria and angioedema.

To report SUSPECTED ADVERSE REACTIONS, contact Zevra Therapeutics, Inc. toll-free at 1-844-600-2237 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

**Drug Interaction(s):**Arimoclomol is an inhibitor of the organic cationic transporter 2 (OCT2) transporter and may increase the exposure of drugs that are OCT2 substrates. When MIPLYFFA is used concomitantly with OCT2 substrates, monitor for adverse reactions and reduce the dosage of the OCT2 substrate.

**Use in Females and Males of Reproductive Potential:**Based on animal findings, MIPLYFFA may impair fertility and may increase post-implantation loss and reduce maternal, placental, and fetal weights.

**Renal Impairment:**The recommended dosage of MIPLYFFA, in combination with miglustat, in patients with an eGFR ≥15 mL/minute to <50 mL/minute is lower than the recommended dosage (less frequent dosing) in patients with normal renal function.

MIPLYFFA capsules for oral use are available in the following strengths: 47 mg, 62 mg, 93 mg, and 124 mg.

October 20, 2026

PDF Version

BOSTON, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced it will report corporate and financial results for the third quarter on Tuesday, November 3, 2026, via a news release after the market close, and will host a conference call/audio webcast at 4:30 p.m. ET that day.

A link to the audio webcast will be accessible on the “Events & Presentations” page in the Investor Relations section of Zevra’s website at investors.zevra.com.

To join via telephone, please use the following dial-in information:

  • (800) 274-8461 (United States)

  • +1 (203) 518-9814 (International)

  • Conference ID: ZVRAQ326

A replay of the webcast will be available for 90 days beginning at approximately 5:30 p.m. ET. The replay will be accessible on the “Events & Presentations” page in the Investor Relations section of Zevra’s website at investors.zevra.com.

About Zevra Therapeutics, Inc.

Zevra Therapeutics, Inc. is a commercial-stage company with a late-stage pipeline committed to redefining what is possible in bringing life-changing therapies to people living with rare diseases. The Company is focused on broadening access through geographic expansion opportunities, progressing its pipeline toward key milestones, and delivering meaningful therapeutics. The commercialization of its lead product, marketed in the U.S. for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a strong corporate foundation and validates its ability to advance therapies from development to market. Zevra's vision is realized through disciplined execution of its strategic plan and core values — patient centricity, integrity, accountability, innovation, and courage — which guide its efforts to deliver long-term value.

September 2, 2026

PDF Version

BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that members of Zevra’s executive leadership team will present at the following investor conferences in New York, NY.

  • Cantor Global Healthcare Conference

  • Fireside chat on Wednesday, September 9, 2026, at 9:10 a.m. ET

  • Morgan Stanley 24thAnnual Global Healthcare Conference

  • Fireside chat on Monday, September 14, 2026, at 5:35 p.m. ET

  • H.C. Wainwright 28th Annual Global Investment Conference

  • Fireside chat on Tuesday, September 15, 2026, at 10:00 a.m. ET

Additionally, management will be available for one-on-one meetings with registered conference attendees. Links to the live webcasts will be accessible on the “Events & Presentations” page in the Investor Relations section of Zevra’s website at investors.zevra.com.

About Zevra Therapeutics, Inc.

Zevra Therapeutics, Inc. is a commercial-stage company with a late-stage pipeline committed to redefining what is possible in bringing life-changing therapies to people living with rare diseases. The Company is focused on broadening access through geographic expansion opportunities, progressing its pipeline toward key milestones, and delivering meaningful therapeutics. The commercialization of its lead product, marketed in the U.S. for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a strong corporate foundation and validates its ability to advance therapies from development to market. Zevra's vision is realized through disciplined execution of its strategic plan and core values — patient centricity, integrity, accountability, innovation, and courage — which guide its efforts to deliver long-term value.

Prompts

Zevra Therapeutics, Inc. (ticker ZVRA), listed in United States.

Company History

Date Change Detail
Nov 20, 2023 Acquired Acquired Acer Therapeutics Inc. (CIK 1069308). Its filings from before the deal are on its own company page, not shown here.
Feb 27, 2023 Renamed KEMPHARM, INC → ZEVRA THERAPEUTICS, INC.

ETFs Holding Zevra Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
JSML 0.66% 250,702 $ 2.384M Jul 31, 2026
JSMD 0.61% 670,077 $ 6.372M Jul 31, 2026
FSCC 0.17% 53,178 $ 624.31K Aug 31, 2026
VFMF 0.15% 127,952 $ 1.502M Aug 31, 2026
AFSM 0.09% 14,273 $ 132.025K Nov 16, 2026
RESM 0.04% 100 $ 1,434.00 Jun 30, 2026
AVSC 0.03% 89,716 $ 829.873K Nov 16, 2026
VFMO 0.02% 39,128 $ 459.363K Aug 31, 2026
DFAS 0.01% 377,613 $ 4.214M Nov 12, 2026
MSSM 0.01% 4,070 $ 47.782K Aug 31, 2026
DFAT 0.01% 155,739 $ 1.738M Nov 12, 2026
DXUV 0.00% 22,935 $ 255.955K Nov 12, 2026
EBI 0.00% 2,161 $ 25.37K Aug 31, 2026
DFAC 0.00% 204,627 $ 2.284M Nov 12, 2026
DFSU 0.00% 5,004 $ 55.845K Nov 12, 2026
DCOR 0.00% 68,153 $ 760.587K Nov 12, 2026
DFUS 0.00% 23,502 $ 262.282K Nov 12, 2026
DFAU 0.00% 13,951 $ 155.693K Nov 12, 2026
AVUS 0.00% 2,327 $ 21.525K Nov 16, 2026
AVUV 0.00% 22,720 $ 210.16K Nov 16, 2026